

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61B 10/00, G01N 33/53, 33/68 G01N 33/543, 33/487, 33/569 B01L 3/00	A1	(11) International Publication Number: <b>WO 94/04078</b> (43) International Publication Date: 3 March 1994 (03.03.94)
---	----	---

(21) International Application Number: PCT/US93/07597

(22) International Filing Date: 13 August 1993 (13.08.93)

(30) Priority data:  
935,845 25 August 1992 (25.08.92) US  
099,926 3 August 1993 (03.08.93) US

(60) Parent Applications or Grants

(63) Related by Continuation  
US 935,845 (CIP)  
Filed on 25 August 1992 (25.08.92)  
US 099,926 (CIP)  
Filed on 3 August 1993 (03.08.93)

(71) Applicant (for all designated States except US): EPITOPE, INC. [US/US]; 8505 S.W. Creekside Place, Beaverton, OR 97005 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only) : THIEME, Thomas, R. [US/US]; 7020 Corvallis Road, Independence, OR 97351 (US). GOLDSTEIN, Andrew, S. [US/US]; 7260 S.W. Ascot, Portland, OR 97225 (US). PIACENTINI, Stephen, C. [US/US]; 3719 S.E. 35th Place, Portland, OR 97202 (US). KLIMKOW, Nanette, M. [US/US]; 3020 S.W. 119th, Beaverton, OR 97005 (US).

(74) Agent: POWERS, Vincent, M.; Law Offices of Peter J. Dehlinger, P.O. Box 60850, Palo Alto, CA 94306-0850 (US).


(81) Designated States: AU, BR, CA, FI, HU, JP, KR, NO, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ORAL COLLECTION DEVICE AND KIT



(57) Abstract

A device (8) for obtaining oral fluid containing substances for testing. In one embodiment, the device includes a syringe (12) having a plunger (11) at the end of which an absorbent pad (10) is attached. A test assembly containing the device (8) is also disclosed.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BV	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LJ	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

ORAL COLLECTION DEVICE AND KIT1. Field of the Invention

The present invention relates to devices and  
5 methods for obtaining oral fluid for testing.

2. References

Parry, J.V., et al., Lancet 2:72-75 (1987).

Thieme, T., et al., J. Clin. Microbiol. 20:1076-  
10 1079 (1992a).

Thieme, T., et al., "Oral Fluid Sampling for  
Determination of HIV-I Antibody Serostatus," Abstract  
from VIII Int'l. Conf. on AIDS, pg. C328 (1992b).

15 3. Background of the Invention

A number of analytical procedures and devices  
are commonly used to test body fluids for the pres-  
ence of substances of diagnostic value. Blood and  
urine are the body fluids of choice. An advantage of  
20 blood as a test fluid is that analytes are often at  
relatively high concentrations, and measurements of  
these concentrations can often provide information  
about a patient's health. Urine is useful for diag-  
nostic testing when the blood component of interest  
25 (e.g., a low molecular weight drug or hormone) is  
concentrated during urine formation. However, the  
urine concentration of an analyte does not usually  
reflect the physiologically active amount of the  
analyte in blood.

30 Although saliva is not commonly used as a body  
fluid in medical diagnosis, numerous studies (Parry,  
et al.; Thieme, et al., 1992 a,b) have demonstrated  
that saliva and other types of oral fluid can provide  
a reliable sample for diagnostic testing involving  
35 antibodies or antigens specific for various human or  
animal pathogens. Oral fluids have also been shown

to be useful in measuring the body levels of naturally occurring hormones or therapeutic and other drugs.

One advantage of sampling oral fluid over sampling blood and urine is the convenience of obtaining the sample. A trained phlebotomist is not required, as is the case with blood, nor are special arrangements for privacy-in-collection and custody of the sample required, as is the case with urine. Furthermore, collection of an oral fluid sample obviates the hazard of handling blood-contaminated needles and tubes.

Devices for the collection of oral fluid have been described. U.S. Patent Nos. 4,418,702 and 4,580,577 show an absorbent pad for absorbing oral fluid, and a barrel-piston arrangement for extracting the fluid from the pad.

U.S. Patent No. 4,774,962 describes an absorbent pad for absorbing saliva, and a centrifuge tube and tube-insert for removing oral fluid from the pad by centrifugation.

U.S. Patent 5,056,521 describes an apparatus for use in monitoring glucose in oral fluid. The apparatus includes a barrel-piston arrangement having a nonreactive absorbent swab secured to the piston. The barrel and piston are used to squeeze the fluid sample from the swab into a glucose monitoring instrument.

#### 4. Summary of the Invention

The present invention includes, in one aspect, a device for collecting oral fluid for diagnostic purposes. The device includes an absorbent pad for recovering a test substance from oral fluid, and a structure (means) for extracting from the pad oral

fluid that has been absorbed into the pad. More specifically, the structure for extracting absorbed oral fluid from the pad includes a syringe having a barrel, and a plunger to which the pad is attached.

5       The absorbent pad may contain various additives, such as preservatives, salts, flavors, and blocking agents for preventing non-specific binding of oral fluid components to the pad. In one preferred embodiment, the pad is impregnated with the salts of a  
10       hypertonic solution, as described further below.

      In another preferred embodiment, the syringe further includes a fluid passageway at the outlet end of the barrel, and detection reagent(s) contained in the passageway, effective to be released into the  
15       oral fluid when such is expelled from the barrel. The passageway may be defined by a cartridge that is detachably mounted on the barrel.

      In a related aspect, the invention includes an assay assembly for use in assaying test substance in  
20       the oral fluid. The assembly includes the above-described pad-syringe structure, and a detection unit constructed for receiving oral fluid expelled therefrom. The detection unit includes a solid-support, and a binding agent attached thereto, effective to  
25       bind specifically to a test substance in the oral fluid when the oral fluid is expelled from the barrel into the unit. The detection unit may be attachable to the outlet end of the syringe, or may be used as a separate fluid-receiving structure.

30       The assembly may further include a passageway that connects the barrel of the syringe in fluid communication with the detection unit. The passageway may contain detection reagent(s) effective to be released into the oral fluid when such is expelled  
35       from the barrel. Preferably, the detection reagent

ent(s) are effective to react with a test substance in the oral fluid to produce on the support, a detectable signal which is dependent on the concentration of the test substance in the oral fluid.

5 In one preferred embodiment of the assembly, the solid-support is a permeable membrane and the detection unit further includes an absorbent material that can be brought into contact with the membrane, to draw fluid through the membrane support.

10 In one configuration, the test substance is an antibody that is diagnostic of infection by a known pathogen. The binding agent can be an antigen that is immunoreactive with the test antibody, in which case the assembly may further include a reporter-labeled reagent effective to bind to the test-substance antibody, when such is bound to the solid-support.

15 Alternatively, the binding agent can selectively bind human antibodies, in which case the assembly may further include a reporter-labeled antigen that is immunoreactive with the test-substance antibody. One exemplary binding agent for binding the test substance antibody is protein A.

20 In another configuration, the test substance is an antigen that is diagnostic of infection by a known pathogen. The binding agent can be an antibody that is immunoreactive with the test antigen, in which case, the assembly may further include a reporter-labeled reagent effective to bind to the test substance antigen, with such bound to the solid-support.

25 In another aspect, the invention includes a solid-support surface for simultaneous assay of both a test substance and a marker substance in an oral-fluid sample, i.e., a substance which gives a positive indication that oral fluid is being tested. The

first and second binding agents for binding the test substance and the marker substance, respectively, may be located on at least partially non-overlapping regions of the surface. Preferably the two binding regions form the two bars of a "+" symbol.

These and other objects and features of the invention will become more fully apparent when the following detailed description of the invention is read in conjunction with the accompanying drawings.

10

#### Brief Description of the Drawings

Figs. 1A and 1B are cross-sectional side views of an oral fluid collection device according to an embodiment of the present invention, shown before (Fig. 1A) and after (Fig. 1B) plunger engagement with a barrel in the device;

Fig. 2 is an assembly view of the plunger and pad in the Fig. 1 device;

Fig. 3A and 3B show alternative cartridge and syringe barrel embodiments;

Fig. 4 shows a cross-sectional side view of a test assembly according to the present invention;

Fig. 5 shows a cross-sectional side view of another embodiment of a test assembly according to the present invention; and

Fig. 6A-6C show exemplary solid-phase formats for detecting a test substance in oral fluid in accordance with the invention;

Fig. 7 shows a solid-support surface arrangement for simultaneously assaying a test substance and a marker substance in oral fluid.

Detailed Description of the InventionA. Oral Fluid Collection Device

Figures 1A and 1B illustrate an oral fluid collection device 8 constructed according to the present invention. The device generally includes an absorbent pad 10, which functions as an oral-fluid collector, a plunger 11 to which the pad is attached, a syringe barrel 12, and in the embodiment shown, a detachable reagent cartridge 13. Plunger 11 includes a plunger stem 14, a sealing gasket 15 located on the inner end of the plunger, and a thumb tab 16 located on the outer end of the plunger.

Fig. 2 shows an assembly view of the plunger and pad. The plunger stem conventionally includes a pair of radial enlargements 18, 20 adjacent its inner end, and terminates in a finger projection 22, as shown. The stem and thumb are preferably formed by injection molding of a suitable polymer, conventionally.

Gasket 15 is a soft rubber or flexible polymer material designed to be received on the plunger, and held in position by enlargements 18, 20, as can be appreciated, with projection 22 extending through the end of the gasket. The diameter of the gasket is such as to form a snug, liquid-tight seal with the interior wall of barrel 12.

Pad 10 is attached to the inner end of plunger 11 by a conventional adhesive, such as the class of silicon rubber adhesives suitable for human oral use. The pad is attached to the stem at contacting surfaces which include the inner face of gasket 15, and the portion of projection 22 which is received within the pad, as can be appreciated from Fig. 2.

The pad can be made of any of a number of absorbent materials suitable for oral use. Preferably, the pad is a thick, absorbent cotton roll or paper,



such as commonly used in dental procedures. An example of such a pad is a 1.5 inch No. 2 medium cotton roll distributed by Patterson Dental Co. (Minneapolis, MN). Materials such as cellulose, polyurethane, polyester, and rayon are also useful.

In one embodiment of the invention, the pad is impregnated with the salts of a hypertonic solution, in an amount effective to recover a high concentration of test substance, such as immunoglobulin, in the oral fluid. As detailed in U.S. Patent 5,103,836, which is incorporated herein by reference, the use of a hypertonic solution results in a constant production of immunoglobulin from other sources within the oral cavity, those sources not being completely understood. By using a hypertonic solution, it is possible to gain an increase of as much as 8-16 times for immunoglobulin than by using distilled water.

A hypertonic solution is a salt solution which has an ionic strength exceeding that found in blood. In general, salts used in the preparation of the hypertonic solution of the present invention are present in an amount of from about 1.5% to about 5% by weight, preferably 3.5% by weight.

Salts which can be used in the preparation of the hypertonic solution include alkali metal compounds as well as alkaline earth metal compounds. Preferred salts include sodium chloride, potassium chloride, magnesium sulfate, magnesium chloride and calcium chloride. Sodium chloride is found to be the least toxic, least expensive and most palatable.

The hypertonic solution can also include a compound or ingredient for stimulating salivation. The compounds capable of stimulating salivation are found to exhibit a sour taste. These compounds

include weak organic acids. Preferred among the weak organic acids are citric acid, ascorbic acid and acetic acid. It is preferred to use citric acid and ascorbic acid at a concentration of between about 0.05% and 0.5% by weight. The preferable range for acetic acid is between about 0.5% and 3.0% by weight.

In order to minimize degradation in a collected specimen, the hypertonic solution can include a preservative. Such a preservative can act to inhibit proteolytic enzymatic activity which can be responsible for the destruction of antibody molecules. Compounds contemplated as a preservative include anti-bacterial agents, anti-fungal agents, bacteriostatic agents, fungistatic agents, and enzyme inhibitors. In a preferred embodiment benzoic acid, sorbic acid or the salts thereof are used as anti-fungal agents. As bacteriostatic agents, salts in high concentration and compounds capable of maintaining the hypertonic solution at low pH are contemplated. Such salts include thimerosal (or merthiolate), phenyl mercuric acetate, phenyl mercuric nitrate and sodium azide. Other preferred preservatives include preservatives which are typically used in medicines and mouthwashes. Examples include ethyl alcohol and chlorhexidine gluconate. Another class of preferred anti-microbial and anti-viral agents are detergents which can be used as topical germicides or in mouthwashes. An example is benzalkonium chloride. It is preferred to use these preservatives in a range of about 0.01% to about 0.2% by weight.

The pad can be impregnated with the hypertonic solution by known means. The hypertonic solution of the present invention can be applied to the pad by dipping the pad into the hypertonic solution so that the salts of the solution can be absorbed into and

onto the pad, removing the pad from the solution and allowing the pad to dry. Typically, the pad is dipped into the hypertonic solution and about 1 ml of solution is absorbed. Alternatively, the hypertonic solution could be sprayed onto the pad until a sufficient amount, preferably about 1 ml is absorbed. Excess liquid is shaken off and the pad is placed in a forced-air, convection drying oven at 50°C for 2 hours or, alternatively, in an oven at 80°C for 6-12 hours in the absence of forced air. After drying, there will be formed a specially treated pad which comprises the salts of the hypertonic solution. It is preferred that as preservatives, salts such as benzalkonium chloride, acetyl pyridinium chloride or chlorhexidine gluconate be used in the preparation of the pad.

Most materials from which the pad can be made can non-specifically bind protein. Thus, some immunoglobulins can undesirably bind to the pad and it is desired to block proteins from binding to the pad by using a blocking agent. Non-specific binding is not normally a problem in the collection of blood samples since blood contains its own blocking agent (i.e., human serum albumin).

To reduce non-specific binding in the collection of oral specimens, a blocking agent can be added to the hypertonic solution to be incorporated into the pad. A blocking agent is generally a soluble protein which is used to prevent non-specific binding of another protein to a solid surface. Compounds which can be added as blocking agents include albumin and gelatin, but any water soluble, non-toxic protein can be used as a blocking agent as long as the protein does not adversely affect the assay being used. It is preferred to use bovine gelatin. In general,

blocking agents can be added to the hypertonic solution of the present invention at a concentration of between about 0.01% and 0.2% by weight. The contents of the hypertonic solution are then incorporated into the pad as described above.

The preferred solution to be used in the preparation of the pad has the following composition:

	component	conc. (wt. %)
10	sodium chloride	3.5%
	citric acid	0.3%
	sodium benzoate	0.1%
	potassium sorbate	0.1%
15	bovine gelatin distilled water addition of 0.1 N sodium hydroxide to increase Ph to about 6.5	0.1%

With reference again to Figs. 1A and 1B, syringe barrel 12 defines an inner wall 24 dimensioned lengthwise to receive the pad and plunger gasket, as shown in Fig. 2A, and in diameter, to snugly receive gasket 15, to form a fluid-tight seal therewith. The barrel has a flanged or radially enlarged opening 26 which facilitates placement of the pad, after oral-fluid-collection, into the barrel. The opposite, inner end of the barrel is provided with a frit 28 which acts as a fluid-permeable filter to allow passage of oral fluid absorbed in the pad to be expelled from the barrel, as the plunger is forced into the barrel. An outlet port 30 at the end of the barrel provides a socket for receiving cartridge 13. In an embodiment of the device which does not include cartridge 13, the outlet end of the barrel may be tapered to a narrow outlet, as in standard syringe

construction. The syringe is also referred to herein as means for extracting oral fluid that has been absorbed into the pad.

Exemplary dimensions for the plunger-pad assembly and barrel according to the present invention are as follows. Plunger 11 is about 3 inches in length, including the length of sealing gasket 15, and about 0.12 inches in diameter. Absorbent pad 10 is about 1.5 inches in length and 0.375 inches in diameter.

10 If a soft rubber gasket is used, a gasket diameter of 0.5 inches and a length of about 0.25 inches is appropriate to form a liquid-tight seal in a syringe barrel having an inner diameter of about 0.4375 inches.

15 Cartridge 13 includes an annular plug 32 which fits snugly into the socket in the barrel, to hold the cartridge firmly in the barrel. An interior passageway 33 through the chamber is provided with a reagent disc 34 impregnated with detection reagent(s)

20 which are released into the oral fluid, preferably as solute components, when oral fluid is expelled through the cartridge. The reagent(s) are for use in detecting selected analyte(s) in the oral fluid, as discussed below. In addition, the reagent(s) may

25 include a blocking agent such as gelatin, milk casein, or bovine serum albumin, suitable for use in certain types of solid-phase assays, also as discussed below. In one embodiment, a reporter-labeled antibody or antigen is dissolved at a concentration

30 of a few mgs/ml in an aqueous solution containing 0.5% gelatin and 30% sucrose (to facilitate solubilization of protein when oral fluid passes through the cartridge). The reagent disk in the cartridge is sandwiched between fluid-permeable frits 35 and 36 in

35 the cartridge chamber.

Additional embodiments for a cartridge and barrel are shown in Figs. 3A and 3B. For example, as shown in Fig. 3A, a barrel outlet 38 can be a male Luer™ fitting 39 for attaching a corresponding female fitting 40 in a cartridge 42. The cartridge includes a rigid frit 44 impregnated with detection reagent(s). A similar arrangement is shown in Fig. 3B except that the male Luer™ fitting 46 of a barrel outlet 48 is recessed in the body of the barrel.

Fig. 3B also shows a barrel configuration in which the interior wall of the barrel is tapered on progressing toward its outlet end, to reduce the amount of oral fluid that remains in the barrel when the pad is compressed.

A strip 50 in the cartridge is a wettable reagent strip which, when wetted by oral fluids passing through the barrel, produces a detectable color change in the presence of analyte in the oral fluids. Analytes such as glucose can be detected using known enzymes, such as glucose oxidase coupled with a peroxidase system effective to produce a detectable color change in the presence of  $H_2O_2$ . In each of the cartridge embodiments illustrated in Figs. 1-3, an interior chamber defines a passageway, such as the interior passageway 33 in cartridge 13, which may contain detection reagent(s) or reagent means effective to be released into the oral fluid when such is expelled from the barrel (Figs. 1 and 2), or effective to mix with oral fluid passing through the passageway (Fig. 3).

Alternatively, the passageway containing the detection reagents may be contained in the outlet end of the barrel, e.g., along the side walls of a barrel outlet, avoiding the need for a separate cartridge.

To collect a substance from the oral cavity with a collection device such as that illustrated in Figs. 1A and 1B, the plunger-pad assembly is placed in the mouth of the patient such that the pad lies entirely within the mouth. Placement of the pad between the lower cheek and gums facilitates absorption of secretions originating from gingival lymphoid tissue as well as secretions from submucosal lymphoid tissue and salivary gland lymphoid tissue. It is preferable that the specimen be collected by rubbing the pad back and forth between the gums for about ten seconds and then holding the pad in position for between about thirty seconds and two minutes. After the pad has been impregnated with oral fluid, the pad is withdrawn from the mouth, and the plunger-pad assembly is placed in the syringe barrel pad-end-first so that oral fluid can be extracted from the pad.

The oral fluid can be stored for later analysis, preferably in a suitable preservation fluid. Alternatively, the oral fluid can be mixed with detection reagent(s) or expelled directly (without detection of reagents) or after mixing with detection reagents on a solid-phase detection device, as described in Section B below.

Alternatively, the reagent(s) introduced into the oral fluid may be designed for assay of an oral-fluid analyte by a solution-phase homogeneous assay. The assay, for example used in detecting an antigen-specific antibody present in oral fluid, can be based on a variety of homogeneous assay formats, for example based on coupled enzymes, fluorescence quenching, or an EMIT configuration (Gosling, J., Clin Chem, 36(8):1408 (1990). Alternatively, the assay may involve immunoprecipitation of an analyte in the oral fluid, leading to a detectable agglutination product,

such as colored microspheres coated with an immuno-precipitin.

From the foregoing, it will be appreciated how various objects and features of the invention are met. The device is convenient for hospital, clinic, or even home use, allowing an oral sample to be collected easily and immediately assayed. The device also reduces the risk of sample contacting the user, since the plunger-pad assembly can be inserted into the syringe barrel following collection of a sample, and can be disposed of, encased in the syringe barrel.

#### B. Oral Fluid Assay Assembly

In another aspect, the invention includes an assembly for detecting a test substance in oral fluid. The assembly generally includes an absorbent-pad syringe device of the type described above, and a detection unit adapted to receive oral fluid expelled from the absorbent pad. The detection unit has a solid-support contained within the detection unit, and a binding agent attached to the solid-support effective to bind specifically to a test substance in the oral fluid when the oral fluid is expelled from the barrel into the unit. The concentration of analyte, e.g., antigen or immunoglobulin, in the oral fluid is then determined by the amount of analyte bound to the support. In one embodiment, the assembly includes a passageway, such as described in section A above, that contains detection reagent(s) (a) effective to be released when oral fluid is expelled from the syringe, and (b) includes one or more reagent components needed to produce a detectable solid-phase binding reaction involving analyte binding to the solid-phase surface.



The choice of assay format depends on the nature of the test substance of interest. Such test substances include a variety of immunoreactive analytes, such as drugs or drug metabolites, for example, cocaine or nicotine or metabolites thereof, viral and bacterial antigens, such as hepatitis B surface antigens, immunoglobulins, particularly IgG and IgM, and hormones, such as  $\beta$ -HCG. Methods for adsorbing or covalently attaching a selected binding agent to the solid support are well known, and include adsorption of biotinylated proteins, such as ovalbumin, to the membrane, with subsequent attachment of the binding agent, in streptavidin-derivatized form, attachment of antibodies to the support through antibodies specific, e.g., against the  $F_c$  portion of the antibodies to be bound, and covalent attachment to surface-derivatizable groups on the membrane, using for example, a variety of available bifunctional coupling reagents.

Two embodiments of an assay assembly according to the present invention are shown in Figs. 4 and 5. In both figures, the lower portion of a syringe collecting device 52, including a syringe 54 and a cartridge 56, are shown. The collecting device has the same construction as that described in Section A above. In the Fig. 4 embodiment, the detection unit, indicated at 60, is attachable to the cartridge for receiving oral fluid expelled from the cartridge. The cartridge may contain detection reagent(s), such as reporter-labeled molecules, which are effective to compete with analyte molecules for binding to the solid support.

Unit 60 generally includes a housing 62 having an inlet port 63 which is attachable to, and in fluid communication with, the outlet side of the cartridge,

as shown. Supported within the housing is a solid-phase support, or membrane 64 which is positioned to receive oral fluid expelled from the syringe device. An absorbent pad 66 is suspended below membrane 64 in  
5 an accordion-like structure 68 to draw oral fluid through the membrane, when the pad is brought into contact with the lower side of the membrane.

Fig. 5 shows a detection unit 70 having a membrane 72 which can be viewed through a window 74,  
10 both supported in a casing 75. An absorbent pad 76 located below the membrane can be brought into contact with the underside of the membrane, to draw fluid through the membrane, by deforming the bottom of the casing.

15 Although the detection units in the assembly embodiments shown in Figs. 4 and 5 are attachable to a syringe device, for receiving oral fluid directly from the syringe, the invention also contemplates an assembly in which the detection unit is a separate  
20 structure, designed to receive oral fluid, e.g., by application of oral fluid and other detection reagents to the membrane in the unit.

A variety of assay configurations which may be employed in the assembly are illustrated in Figures  
25 6A, 6B, and 6C. In Fig. 6A, a test substance 80 (an antibody), is captured on a solid-support 82 by immunospecific binding to a support-bound antigen 84. The captured analyte can in turn be detected by a reporter-labeled anti-human antibody 86.

30 Fig. 6B shows a solid-phase support 88 for detecting a test antibody 90. The analyte antibody is bound to the solid-phase membrane by a binding agent 92, such as protein A or an anti-human immunoglobulin, which is carried on the solid support.  
35 Bound analyte antibody can be detected by a reporter-

labeled antigen 94 that is immunoreactive with the test antibody.

Fig. 6C shows a solid-support 96 for use in detecting an antigen analyte 98 in the oral fluid.

5 The binding agent in the unit is an antigen-specific antibody 100. Antigen-analyte bound to the support can be detected with a detection reagent which includes a reporter-labeled antibody which is immunoreactive with a second epitopic site on the analyte.

10 Alternatively, the detection reagent may be a reporter-labeled antigen which competes with the analyte antigen for binding to the solid-support binding agent.

Conveniently, the reporter in the above detection reagents is an enzyme, detectable by addition of

15 a suitable substrate, or a fluorescent reporter.

An assay for a test substance in oral fluid can include a simultaneous assay for a marker substance, as described further below. In a typical assay for

20 an oral fluid sample using the solid-support surface of the present invention, the test substance is an antibody that is immunoreactive with an HIV-1 peptide, and the marker substance is transferrin. The solid-support surface includes protein A attached to

25 a first region of the membrane surface, for binding human antibodies, and an anti-transferrin antibody attached to a second region of the membrane surface, effective to capture transferrin. To detect the HIV-1 antibody and transferrin, the assay includes a

30 horseradish peroxidase conjugate of the HIV-1 peptide for which the test HIV-1 antibody is specific, and a horseradish peroxidase conjugate of an anti-transferrin antibody that can bind transferrin irrespective of whether the first anti-transferrin antibody

35 has also bound to the same transferrin molecule.

Preferably, the second anti-transferrin antibody is from chicken, since chicken antibodies do not bind to protein A. The reporter-labeled reagents may be impregnated in dried form in a reagent disk which is then placed in a reagent cartridge. The cartridge is then attached to an oral fluid collection device according to the present invention. An oral fluid sample is collected from a patient using the device, and the oral fluid is expressed from the syringe barrel and through the reagent cartridge attached thereto. The reporter-labeled reagents are taken up by and dissolved into the oral fluid as the fluid passes through the cartridge, allowing reaction of the reagents with the respective test and marker substances. The outlet of the cartridge is directed so that the reagent/oral fluid mixture is dispensed onto the solid-support surface. A few drops (~300  $\mu$ l) of the mixture should be sufficient. The mixture is allowed to remain on the solid-support surface for a time (~5 minutes) sufficient to allow the test substance and the marker substance to bind to the respective detection reagents as well as to the respective binding regions on the solid-support surface. The mixture is then removed from the surface.

In another embodiment, the test substance is a *Helicobacter pylori* antibody, and the reporter-labeled reagent is a reporter-labeled *Helicobacter pylori* antigen.

If the solid-support surface is part of a detection unit according to the assay assembly of the present invention described above, the mixture can be removed by contacting an absorbent pad with the underside of the solid-support to draw the fluid therethrough. Finally, a solution containing hydrogen peroxide and a chromogenic substrate (tetrameth-

ylbenzidine, in this example) of horseradish peroxidase is dispensed onto the membrane. Any horseradish peroxidase bound to the solid-support via a test substance or marker substance produces a colored precipitate on the region to which the peroxidase has become bound. The presence of the marker substance and/or test substance is then determined from the pattern that is produced on the solid-support surface.

10 In one particular aspect of the present invention, an oral fluid sample is simultaneously assayed for a marker substance that is always present in oral fluid, in order to validate the result of the assay for the test substance. Detection of such a marker  
15 substance in the sample provides a positive indication that the sample contains oral fluid. Suitable marker substances include transferrin, albumin, ceruloplasmin, and amylase, for example (see "Human Saliva: Clinical Chemistry and Microbiology, Vols. I and II, Tenovuo, J.O., Ed., CRC Press, Boca Raton, Florida (1989)). Marker substances that derive from blood (e.g., albumin and transferrin) are particularly useful when the test substance is also blood-derived (e.g., IgG).

25 Preferably, both the test substance and the marker substance are assayed using an assay assembly wherein the solid-support includes a flat surface. Preferably, the solid-support is a microporous membrane which can be made of materials such as nitrocellulose or polyvinylidene difluoride, for example.  
30 The first and second binding agents for the test substance and the marker substance, respectively, are located on at least partially different (non-overlapping) regions of the surface so that binding of the  
35 test and marker substances to the solid-support

surface can be distinguished. Methods for binding such binding reagents, both by covalent as well as non-covalent means, are well known in the art. Preferably, the regions are configured to give rise to recognizable patterns that upon viewing can readily convey the result of the assay.

Although the preceding example describes the use of horseradish peroxidase as the reporter, it should be readily appreciated that other enzymes as well as non-enzyme reporters could be used. Moreover, although using identical reporters is convenient, the reporter used to detect the test substance need not be the same as that used to detect the marker substance. In addition, other binding formats can be utilized. For example, in an assay for hepatitis B surface antigen in oral fluid, the binding agent on the solid-support can be a first antibody immunoreactive with the antigen, and the detection reagent can be a reporter-labeled second antibody.

One exemplary solid-support surface pattern for conveying the result of the assay is shown in Figure 7. Bar-shaped regions 104 and 106 in the figure are regions of a solid support 108 which are derivatized or otherwise treated with binding agents which, respectively, are immunospecific or otherwise reactive with a selected oral-fluid marker, such as transferrin, and a selected oral-fluid analyte, such as an antigen-specific analyte. As shown, the two regions are arranged to form a "+" symbol. As can be appreciated, color development in the marker region 104, but not in the analyte region 106 will produce a "-" pattern, indicating that the sample fluid contains the oral-fluid marker, but not the analyte being tested. When such analyte is present, a "+" symbol is observed.

Although the invention has been described with respect to particular embodiments, it will be appreciated that various changes and modifications can be made without departing from the invention.

## IT IS CLAIMED:

1. A device for obtaining oral fluid that contains substances for testing comprising:

an absorbent pad for recovering a test substance  
5 from oral fluid;

means for extracting from the pad oral fluid that has been absorbed into the pad, wherein said means includes a syringe composed of a barrel, and a plunger having an inner end to which the absorbent  
10 pad is attached.

2. The device of claim 1, wherein said pad is impregnated with the salts of a hypertonic solution.

15 3. The device of claim 2, wherein the test substance is an antibody, and the hypertonic solution includes about 3.5% sodium chloride, about 0.3% citric acid, about 0.1% potassium sorbate, about 0.1% sodium benzoate, and about 0.1% bovine gelatin.

20 4. The device of claim 1, wherein the barrel has a radially enlarged opening through which the plunger is received.

25 5. The device of claim 1, which further includes a fluid passageway at the outlet end of the barrel, and which further includes a detection reagent means contained in said passageway, effective to be released into the oral fluid when oral fluid is  
30 expelled from the barrel.

6. The device of claim 5, wherein the fluid passageway is defined by a cartridge that is detachably mounted on the barrel.



7. The device of claim 5, wherein the reagent means includes reagents effective to react with a test substance in the oral fluid to produce a detectable color change.

5

8. The device of claim 5, wherein the detection reagent means includes reagents effective to react with and agglutinate a test substance in the oral fluid to produce a detectable precipitate.

10

9. The device of claim 5, which further includes an absorbent strip in fluid communication with the passageway, said strip containing detecting reagents effective to produce a detectable color change when the strip is wetted by the oral fluid, when a test substance is present in the oral fluid.

15

10. An assembly for detecting a test substance in oral fluid comprising:

20 an absorbent pad for recovering test substance from oral fluid;

a syringe composed of a barrel, and a plunger having an inner end to which the pad is attached, for extracting from the pad oral fluid that has been absorbed into the pad; and

25

a detection unit adapted to receive oral fluid expelled from the absorbent pad, said unit having a solid-support contained within the detection unit, and a binding agent attached to the solid-support effective to bind specifically to a test substance in the oral fluid when the oral fluid is expelled from the barrel into the unit.

30

11. The assembly of claim 10, wherein said pad is impregnated with the salts of a hypertonic solu-

35

tion, said salts being present in the pad in an amount effective to recover a high concentration of test substance from oral fluid.

5           12. The assembly of claim 10, wherein the test substance is an antibody that is diagnostic of infection by a known pathogen, the binding agent is an antigen that is immunoreactive with such an antibody, and the assembly further includes a reporter-labeled  
10 reagent effective to bind to the test substance antibody when the test substance antibody is bound to the solid-support.

15           13. The assembly of claim 10, wherein the test substance is an antibody that is diagnostic of infection by a known pathogen, the binding agent is effective for selectively binding human antibodies, and the assembly further includes a reporter-labeled antigen that is immunoreactive with the test sub-  
20 stance antibody.

14. The assembly of claim 12, wherein the binding agent is protein A.

25           15. The assembly of claim 13, wherein the test substance is an HIV-1 antibody, and the reporter-labeled reagent is a reporter-labeled HIV-1 peptide.

30           16. The assembly of claim 13, wherein the test substance is a *Helicobacter pylori* antibody, and the reporter-labeled reagent is a reporter-labeled *Helicobacter pylori* antigen.

35           17. The assembly of claim 10, which includes a passageway that connects the barrel in fluid communi-

cation with the detection unit, and said passageway contains detection reagent means effective to be released into the oral fluid when such is expelled from the barrel.

5

18. The assembly of claim 17, wherein said passageway is defined by a cartridge that is detachably connected to said barrel and detection unit.

10

19. The assembly of claim 17, wherein the detection reagent means includes a reagent effective to react with a test substance in the oral fluid to produce a level of binding of the substance to the solid-support which is dependent on the concentration of the test substance in the oral fluid.

15

20. The assembly of claim 10, wherein the solid-support is a permeable membrane and the detection unit further includes an adsorbent material that can be brought into contact with the membrane.

20

21. The assembly of claim 10, for assaying simultaneously for a test substance and a marker substance in an oral fluid sample, wherein the solid-support is a membrane comprising:

25

a first region to which is attached a first binding agent effective to bind specifically to a test substance in oral fluid;

a second region to which is attached a second binding agent effective to bind specifically to a marker substance in such oral fluid, the second region being at least partially non-overlapping with the first region;

30

means for visualizing test substance bound to said first region; and

35

means for visualizing marker substance bound to said second region;

whereby oral fluid containing the marker substance and not the test substance gives rise to a pattern on the solid-support surface that is distinguishable from a pattern that appears for oral fluid containing both the marker substance and the test substance.

22. A solid-support surface for use in simultaneously assaying for a test substance and a marker substance in oral fluid comprising:

a first region to which is attached a first binding agent effective to bind specifically to a test substance in oral fluid;

a second region to which is attached a second binding agent effective to bind specifically to a marker substance in such oral fluid, the second region being at least partially non-overlapping with the first region;




means for visualizing test substance bound to said first region; and

means for visualizing marker substance bound to said second region;

whereby oral fluid containing the marker substance and not the test substance gives rise to a pattern on the solid-support surface that is distinguishable from a pattern that appears for oral fluid containing both the marker substance and the test substance.

23. The solid-support surface of claim 22, wherein said first and second regions are bar-shaped and overlap to form a "+" symbol.








Fig. 6A




Fig. 6B




Fig. 6C




Fig. 7

## INTERNATIONAL SEARCH REPORT

Application No  
PCT/US 93/07597

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 A61B10/00 G01N33/53 G01N33/68 G01N33/543 G01N33/487  
G01N33/569 B01L3/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61B G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	US,A,5 056 521 (PARSONS) 15 October 1991 see column 3, line 41 - column 4, line 5  see column 4, line 29 - line 38; figures 2,4-6 cited in the application ---	1,4 2,3,5,7, 9,10
Y A	WO,A,91 13355 (EPITOPE) 5 September 1991 see page 6, line 26 - page 7, line 21 see page 9, line 13 - line 33; figures cited in the application ---	2,3 11
Y A	US,A,4 635 488 (KREMER) 13 January 1987 see column 4, line 60 - column 5, line 20 see column 8, line 23 - line 66; claim 23; figures ---	5,7,9 17
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*B\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

7 December 1993

Date of mailing of the international search report

22. 12. 93

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tlx. 31 651 cpo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Klein, C



## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 93/07597

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 414 513 (CANCER DIAGNOSTICS) 27 February 1991	10
A	see column 3, line 20 - line 24	5,6, 12-14, 17-19, 21,22
	see column 4, line 33 - column 6, line 18; figures	
X	EP,A,0 056 241 (METPATH) 21 July 1982 see the whole document cited in the application	1
A	WO,A,91 14944 (TENTA PROPERTIES) 3 October 1991  see page 1, line 5 - line 18; claims 1,3,5,10,11	7,9,10, 12-15, 19-22
A	US,A,4 774 962 (HEBEL) 4 October 1988 cited in the application	
A	EP,A,0 404 527 (CANCER DIAGNOSTICS) 27 December 1990	

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 93/07597

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5056521	15-10-91	NONE	
WO-A-9113355	05-09-91	US-A- 5103836	14-04-92
		AU-A- 7460991	18-09-91
		CA-A- 2023636	22-03-91
		EP-A- 0418739	27-03-91
		EP-A- 0516746	09-12-92
		JP-A- 3143435	19-06-91
		US-A- 5234001	10-08-93
US-A-4635488	13-01-87	NONE	
EP-A-0414513	27-02-91	US-A- 5003988	02-04-91
		AU-A- 6117490	28-02-91
		JP-A- 3170059	23-07-91
		US-A- 5016644	21-05-91
		US-A- 5133363	28-07-92
EP-A-0056241	21-07-82	CA-A- 1170527	10-07-84
		JP-A- 57145648	08-09-82
		US-A- 4418702	06-12-83
		US-A- 4580577	08-04-86
WO-A-9114944	03-10-91	AU-A- 7684791	21-10-91
		EP-A- 0474858	18-03-92
		OA-A- 9402	15-09-92
US-A-4774962	04-10-88	DE-A- 3632303	02-04-87
EP-A-0404527	27-12-90	US-A- 5024237	18-06-91
		AU-A- 5767890	03-01-91
		JP-A- 3128461	31-05-91
		US-A- 5003988	02-04-91
		US-A- 5016644	21-05-91
		US-A- 5133363	28-07-92